BYROW replaces thousands of table formulas with one spill formula, making spreadsheets leaner and much more robust.
As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...